112 related articles for article (PubMed ID: 12684687)
1. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
Fedier A; Steiner RA; Schwarz VA; Lenherr L; Haller U; Fink D
Int J Oncol; 2003 May; 22(5):1169-73. PubMed ID: 12684687
[TBL] [Abstract][Full Text] [Related]
2. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites.
Fedier A; Schlamminger M; Schwarz VA; Haller U; Howell SB; Fink D
Ann Oncol; 2003 Jun; 14(6):938-45. PubMed ID: 12796033
[TBL] [Abstract][Full Text] [Related]
3. Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2.
Fedier A; Ruefenacht UB; Schwarz VA; Haller U; Fink D
Br J Cancer; 2002 Oct; 87(9):1027-33. PubMed ID: 12434296
[TBL] [Abstract][Full Text] [Related]
4. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest.
Yun J; Zhong Q; Kwak JY; Lee WH
Oncogene; 2005 Jun; 24(25):4009-16. PubMed ID: 15782115
[TBL] [Abstract][Full Text] [Related]
6. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.
Treszezamsky AD; Kachnic LA; Feng Z; Zhang J; Tokadjian C; Powell SN
Cancer Res; 2007 Aug; 67(15):7078-81. PubMed ID: 17671173
[TBL] [Abstract][Full Text] [Related]
7. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest.
Ongusaha PP; Ouchi T; Kim KT; Nytko E; Kwak JC; Duda RB; Deng CX; Lee SW
Oncogene; 2003 Jun; 22(24):3749-58. PubMed ID: 12802282
[TBL] [Abstract][Full Text] [Related]
9. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
Reedy MB; Hang T; Gallion H; Arnold S; Smith SA
Gynecol Oncol; 2001 Jun; 81(3):441-6. PubMed ID: 11371136
[TBL] [Abstract][Full Text] [Related]
10. Mammary tumor formation in p53- and BRCA1-deficient mice.
Cressman VL; Backlund DC; Hicks EM; Gowen LC; Godfrey V; Koller BH
Cell Growth Differ; 1999 Jan; 10(1):1-10. PubMed ID: 9950212
[TBL] [Abstract][Full Text] [Related]
11. The role of p53 in death of IL-3-dependent cells in response to cytotoxic drugs.
Palacios C; Gutierrez del Arroyo A; Silva A; Collins MK
Oncogene; 2000 Jul; 19(31):3556-9. PubMed ID: 10918614
[TBL] [Abstract][Full Text] [Related]
12. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability.
Shen SX; Weaver Z; Xu X; Li C; Weinstein M; Chen L; Guan XY; Ried T; Deng CX
Oncogene; 1998 Dec; 17(24):3115-24. PubMed ID: 9872327
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 signals ARF-dependent stabilization and coactivation of p53.
Somasundaram K; MacLachlan TK; Burns TF; Sgagias M; Cowan KH; Weber BL; el-Deiry WS
Oncogene; 1999 Nov; 18(47):6605-14. PubMed ID: 10597265
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
DelloRusso C; Welcsh PL; Wang W; Garcia RL; King MC; Swisher EM
Mol Cancer Res; 2007 Jan; 5(1):35-45. PubMed ID: 17259345
[TBL] [Abstract][Full Text] [Related]
15. A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint.
Wang RH; Yu H; Deng CX
Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17108-13. PubMed ID: 15563594
[TBL] [Abstract][Full Text] [Related]
16. A role for Brca1 in chromosome end maintenance.
McPherson JP; Hande MP; Poonepalli A; Lemmers B; Zablocki E; Migon E; Shehabeldin A; Porras A; Karaskova J; Vukovic B; Squire J; Hakem R
Hum Mol Genet; 2006 Mar; 15(6):831-8. PubMed ID: 16446310
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs.
Koivusalo R; Krausz E; Helenius H; Hietanen S
Mol Pharmacol; 2005 Aug; 68(2):372-82. PubMed ID: 15908516
[TBL] [Abstract][Full Text] [Related]
18. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy.
Unruh A; Ressel A; Mohamed HG; Johnson RS; Nadrowitz R; Richter E; Katschinski DM; Wenger RH
Oncogene; 2003 May; 22(21):3213-20. PubMed ID: 12761491
[TBL] [Abstract][Full Text] [Related]
19. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
20. Activation of p53 protein in normal and in tumor cells by a novel anticancer agent CHS 828.
Wojciechowski J; Lövborg H; Wesierska-Gadek J
Drugs Exp Clin Res; 2003; 29(2):53-67. PubMed ID: 12951835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
